Evidence map›Paper›PMID 27737772›Full record

ReviewBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2017

The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies.

Andrew C Dietz, Christine N Duncan, Blanche P Alter, Dorine Bresters, Morton J Cowan, Luigi Notarangelo, Philip S Rosenberg, Shalini Shenoy, Roderick Skinner, Mark C Walters and 3 more

Open access · hybridAbstract readConsensus StatementReview
In one paragraph

Review in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
11.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
    Trial
  4. Review
  5. Parent Reports of Developmental Service Utilization After Newborn Screening.International journal of neonatal screening · 2024
    Article
  6. Review
  7. Article
  8. Article
  9. Exploring the long-term psychosocial impact of paediatric haematopoietic stem cell transplantation for nonmalignant diseases.Health expectations : an international journal of public participation in health care and health policy · 2022
    Article
  10. Article
  11. Review
  12. Review
  13. Observational
  14. Review
  15. Review
  16. Review
  17. Inherited bone marrow failure syndromes: considerations pre- and posttransplant.Hematology. American Society of Hematology. Education Program · 2017
    Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 3 countries.

Andrew C DietzChildren's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California.
Christine N DuncanDana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
Blanche P AlterClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Dorine BrestersWillem-Alexander Children's Hospital, SCT Unit, Leiden University Medical Center, Leiden, The Netherlands.
Morton J CowanUniversity of California San Francisco, Department of Pediatrics, Allergy, Immunology, and Blood and Marrow Transplant Division, San Francisco, California.
Luigi NotarangeloDivision of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Philip S RosenbergBiostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Shalini ShenoySt. Louis Children's Hospital, Washington University, St. Louis, Missouri.
Roderick SkinnerGreat North Children's Hospital and Northern Institute of Cancer Research, Newcastle upon Tyne, United Kingdom.
Mark C WaltersUCSF Benioff Children's Hospital Oakland, Oakland, California.
John WagnerBlood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota.
K Scott BakerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Michael A PulsipherChildren's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California. Electronic address: mpulsipher@chla.usc.edu.
Children's Hospital of Los Angeles · USNational Cancer Institute · USBoston Children's Hospital · USDana-Farber/Boston Children's Cancer and Blood Disorders Center · USFred Hutch Cancer Center · USInstitute of Cancer Research · GBLeiden University Medical Center · NLSt. Louis Children's Hospital · USUCSF Benioff Children's Hospital · USUniversity of California, San Francisco · USUniversity of Minnesota · US

Funding

Clinical Genetic Studies of Familial and Hereditary Cancer SyndromesZIACP010144 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SAVAGE, SHARON A. · 2009 to 2025
$111.8M
Training of Clinical Investigators in Primary Immune DeficienciesU54AI082973 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PAI, SUNG-YUN · 2009 to 2023
$23.3M
Pediatric Blood and Marrow Transplant ConsortiumU01HL069254 · NHLBI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI PULSIPHER, MICHAEL A · 2001 to 2010
$2.0M
BONE MARROW TRANSPLANT (BMT) SURVIVORS STUDYR01CA078938 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI BHATIA, SMITA · 2000 to 2003
$1.6M
Unrelated Donor BMT vs. Immune Suppression for Newly Diagnosed Severe Aplastic Anemia in Children and Young Adults: BMT CTN Core Center Renewal for the Pediatric Blood and Marrow Transplant ConsortiumUG1HL069254 · NHLBI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KEAN, LESLIE S · 2017 to 2023
$1.3M
Blood and Marrow Transplant Clinical Trials NetworkU10HL069254 · NHLBI · UNIVERSITY OF UTAH · PI PULSIPHER, MICHAEL A · 2011 to 2016
$839k
Primary Immune Deficiency Treatment Consortium Annual Scientific MeetingR13AI094943 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PUCK, JENNIFER M. · 2011 to 2025
$239k
Late Effects after Pediatric HSCT: State of the Science, Future DirectionsR13CA159788 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI BAKER, KEVIN S, PULSIPHER, MICHAEL A · 2011 to 2011
$13k
NCI NIH HHS R01 CA078938NCI NIH HHS R13 CA159788NHLBI NIH HHS U01 HL069254NHLBI NIH HHS U10 HL069254NHLBI NIH HHS UG1 HL069254NIAID NIH HHS R13 AI094943NIAID NIH HHS U54 AI082973
6 · The paper itself

Abstract

An international consensus conference sponsored by the Pediatric Blood and Marrow Transplant consortium entitled "Late Effects Screening and Recommendations Following Allogeneic Hematopoietic Cell Transplant for Immune Deficiency and Nonmalignant Hematologic Disease" was held in Minneapolis, Minnesota on May 10, 2016 and May 11, 2016. The purpose of the conference was to address the unmet need for greater understanding of and the screening for long-term complications in the growing population of survivors of transplantation for nonmalignant disorders. The conference focused on transplantation for hemoglobinopathy, immune deficiency, and inherited bone marrow syndromes. A multidisciplinary group of experts in the disease areas and transplantation late effects presented the current state of understanding of how the underlying disease, pretransplantation therapies, and transplantation-related factors uniquely interact to influence the development of late toxicities. Recommendations were put forth by the group for the late effects screening of survivors of transplantation for these nonmalignant disorders. The findings and recommendations that came from this conference will be presented in a series of 6 additional manuscripts in the upcoming months. In this manuscript, we explore the need for screening practices specific to the survivors of transplantation for nonmalignant diseases and the methodologic challenges associated with the study of these patients.

Indexed as

Bone Marrow DiseasesChildHealth Planning GuidelinesHematopoietic Stem Cell TransplantationHemoglobinopathiesHumansImmunologic Deficiency SyndromesLong Term Adverse EffectsMass ScreeningSurvivorsHemoglobinopathiesImmune deficienciesLate effectsMarrow failure disordersPediatric allogeneic bone marrow transplantation

Identifiers

PMID27737772
PMCPMC5267609
OpenAlexW2546994869

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.